The only FDA-approved nasal spray for adults with treatment-resistant depression, reduces depression symptoms when two or more oral antidepressants haven’t worked.

 

SPRAVATO® (esketamine) CIII Nasal Spray is indicated for the treatment of:

•     Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant.

•     Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.

Treatment with Spravato (esketamine) is easy:

• Therapy sessions are conducted in your Spravato doctor’s office

• You are awake during treatment

• There are no negative effects on memory or sleep

• It’s covered by most health insurance plans, including Medicare and Tricare